Contact lenses, particularly the extended wear variety, render wearers vulnerable to eye infections from Pseudomonas aeruginosa. These infections can cause severe damage, including blindness. Treating the eye with antibodies to the inflammatory immune compound interleukin-17 (IL-17) reduced eye damage and the number of bacteria in a mouse model. The research is published in the October 2012 issue of Infection and Immunology.
The onslaught of Pseudomonas infection of the eye is often swift, and is aggravated by the bacterium's resistance to antibiotics. "Pseudomonas is everywhere in the environment, and can be unwittingly introduced into the lens cleaning solution, or directly onto the contact lens, so everyone who uses contact lenses is at risk," says principal investigator Gregory P. Priebe of Brigham and Women's Hospital in Boston, and Boston Children's Hospital.
Immune cells known as neutrophils are a major cause of the eye damage that ensues from Pseudomonas infection. IL-17 is involved in attracting neutrophils to the infected tissues. They are the vanguard of immune attack, arriving at a site of infection within an hour, trapping, and ingesting pathogens. In their pathogen-killing function, they also release noxious substances, notably elastase, an enzyme that can chew up tissues, and superoxide, which is converted into hypochlorous acid, more commonly known as chlorine bleach. Thus, the ensuing eye damage is not surprising.
Nonetheless, the strategy of blocking these pathogen killing cells risked reducing the immune system's bacteria-killing function, says Priebe. "Surprisingly, just the opposite was seen: blocking IL-17 with antibodies led both to fewer neutrophils in the eye, and to fewer bacteria," says Priebe. Thus, he says, the research may lead to effective treatments.
"We thought that blocking IL-17 infection might worsen eye infections, but found just the opposite,' says Priebe . "Interestingly, this is a common pattern in eye infections. The body's responses that make the damage worse are often the same things needed to limit infections in other tissues, such as the lung."
Reference: Zaidi TS, et al Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect. Immun. 80:3706-3712. 2012.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.